---
title: Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel
  in Relapsed/Refractory Multiple Myeloma
date: '2025-02-18'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39965175/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20250219171040&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: 'CONCLUSION: Cilta-cel demonstrated superior efficacy and survival, with
  higher incidence of certain toxicities, compared with ...'
disable_comments: true
---
CONCLUSION: Cilta-cel demonstrated superior efficacy and survival, with higher incidence of certain toxicities, compared with ...